Vanguard Group Inc. Has $361.96 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Vanguard Group Inc. reduced its stake in Ultragenyx Pharmaceutical by 0.4%, owning 9,996,226 shares valued at approximately $361.96 million as of the latest SEC filing.
• Ultragenyx Pharmaceutical reported a 13.2% increase in revenue to $166.50 million for the most recent quarter, outperforming analysts' estimates.
• Several analysts have adjusted their price targets for Ultragenyx, with consensus ratings indicating a "Moderate Buy" and a target price averaging $81.50.

Vanguard Group Inc. decreased its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 0.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,996,226 shares of the biopharmaceutical company's stock after selling 38,636 shares during the period. Vanguard Group Inc. owned approximately 10.65% of Ultragenyx Pharmaceutical worth $361,963,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. GAMMA Investing LLC grew its stake in shares of Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 323 shares during the last quarter. ANTIPODES PARTNERS Ltd acquired a new position in shares of Ultragenyx Pharmaceutical in the 1st quarter worth approximately $57,000. GF Fund Management CO. LTD. acquired a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter worth approximately $82,000. Quarry LP acquired a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter worth approximately $84,000. Finally, PNC Financial Services Group Inc. grew its stake in shares of Ultragenyx Pharmaceutical by 231.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,737 shares of the biopharmaceutical company's stock worth $99,000 after purchasing an additional 1,911 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE stock traded up $0.16 during trading on Thursday, hitting $29.52. 1,170,353 shares of the company were exchanged, compared to its average volume of 1,779,487. The firm has a market capitalization of $2.84 billion, a price-to-earnings ratio of -5.34 and a beta of 0.25. The business's 50-day simple moving average is $31.85 and its 200 day simple moving average is $35.89. Ultragenyx Pharmaceutical Inc. has a twelve month low of $25.81 and a twelve month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.10. The business had revenue of $166.50 million during the quarter, compared to analysts' expectations of $161.37 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The firm's quarterly revenue was up 13.2% compared to the same quarter last year. During the same period last year, the company posted ($1.52) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Wells Fargo & Company lowered their price objective on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a research note on Thursday, July 10th. Guggenheim reissued a "buy" rating and issued a $64.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Morgan Stanley dropped their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, July 14th. HC Wainwright raised shares of Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 target price on the stock in a research report on Monday, July 28th. Finally, William Blair started coverage on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They issued an "outperform" rating and a $65.00 target price on the stock. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $81.50.

Insider Activity at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $37.39, for a total transaction of $89,922.95. Following the completion of the sale, the director directly owned 15,344 shares in the company, valued at approximately $573,712.16. This trade represents a 13.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 5.50% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.